Japanese drug major Daiichi Sankyo has filed a supplemental New Drug Application with the US Food and Drug Administration for WelChol (colesevelam HCl) as a drug to improve glycemic control in patients with type 2 diabetes. If approved, the agent will be the first cholesterol-lowering medication also cleared for this indication. Clinical studies have shown that WelChol lowers HbA1C in these patients. A study presented at the American Heart Association's 2006 meeting, showed that WelChol plus insulin demonstrated a mean HbA1C reduction of 0.5% compared to placebo (-0.41% versus +0.09%, p<0.007).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze